dosing of retatrutide Guide for Researchers Retatrutide Dosing: Early Clinical Trial

Caixas, C

Liraglutide for managing overweight and obesity Recommendations chapter (TA664)

KFF reported in May 2024 that about 1 in 8 U.S

Specifically, those taking GLP-1 Shot lost an average of 16% of their initial body weight, while individuals taking Liraglutide lost an average of 6%.* Here is a look at some of the impressive weight loss before and after results from people using GLP-1 Shot injections

GLP-1, or Glucagon-like peptide, is a hormone naturally secreted by the intestines

Retatrutide is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) not yet licensed by the MHRA or EMA, with Phase 2 data suggesting significant weight reduction but Phase 3 confirmation still required